120 related articles for article (PubMed ID: 30023090)
21. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].
Piffer S; Zeni G; Aldovini D; Polla E; Peterlongo P
Minerva Med; 1989 Apr; 80(4):405-10. PubMed ID: 2725943
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Luo L; Shi HZ; Liang QL; Jiang J; Qin SM; Deng JM
Respir Med; 2010 Jan; 104(1):149-56. PubMed ID: 19945835
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis.
Chen N; Liu S; Huang L; Li W; Yang W; Cong T; Ding L; Qiu M
Oncotarget; 2017 Aug; 8(34):57460-57469. PubMed ID: 28915685
[TBL] [Abstract][Full Text] [Related]
25. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.
Cavallari I; Urso L; Sharova E; Pasello G; Ciminale V
Front Oncol; 2019; 9():740. PubMed ID: 31475103
[TBL] [Abstract][Full Text] [Related]
26. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.
Sheffield BS; Tinker AV; Shen Y; Hwang H; Li-Chang HH; Pleasance E; Ch'ng C; Lum A; Lorette J; McConnell YJ; Sun S; Jones SJ; Gown AM; Huntsman DG; Schaeffer DF; Churg A; Yip S; Laskin J; Marra MA
PLoS One; 2015; 10(3):e0119689. PubMed ID: 25798586
[TBL] [Abstract][Full Text] [Related]
27. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Orui H; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Nakano T; Hasegawa S
Ann Surg Oncol; 2012 Dec; 19(13):4229-37. PubMed ID: 22825770
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.
Tammilehto L; Maasilta P; Kostiainen S; Appelqvist P; Holsti LR; Mattson K
Respiration; 1992; 59(3):129-35. PubMed ID: 1439223
[TBL] [Abstract][Full Text] [Related]
29. Predicting survival in malignant mesothelioma.
Musk AW; Olsen N; Alfonso H; Reid A; Mina R; Franklin P; Sleith J; Hammond N; Threlfall T; Shilkin KB; de Klerk NH
Eur Respir J; 2011 Dec; 38(6):1420-4. PubMed ID: 21737558
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy advances for mesothelioma treatment.
Bakker E; Guazzelli A; Ashtiani F; Demonacos C; Krstic-Demonacos M; Mutti L
Expert Rev Anticancer Ther; 2017 Sep; 17(9):799-814. PubMed ID: 28724330
[TBL] [Abstract][Full Text] [Related]
31. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography predicts survival in malignant pleural mesothelioma.
Flores RM; Akhurst T; Gonen M; Zakowski M; Dycoco J; Larson SM; Rusch VW
J Thorac Cardiovasc Surg; 2006 Oct; 132(4):763-8. PubMed ID: 17000285
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
34. [Pericardial mesothelioma. Apropos of a case].
Bertinchant JP; Wojewodzka H; Novati JP; Baldet P; Marty-Double C; Gleizes JL; Modrin C; Henry P; Schuh D; Mary H
Arch Mal Coeur Vaiss; 1987 Jun; 80(7):1193-6. PubMed ID: 3118843
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
Schouwink H; Korse CM; Bonfrer JM; Hart AA; Baas P
Lung Cancer; 1999 Jul; 25(1):25-32. PubMed ID: 10466859
[TBL] [Abstract][Full Text] [Related]
36. Early cytological diagnosis of diffuse malignant mesothelioma of the peritoneum: a case report.
Pomjanski N; Grote HJ; Sander O; Heikaus S; Müller KM; Böcking A
Diagn Cytopathol; 2008 Feb; 36(2):120-3. PubMed ID: 18181185
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis of malignant mesothelioma by fine needle aspiration of a cervical lymph node. A case report.
Ansari NA; Derias NW
Acta Cytol; 2000; 44(1):70-4. PubMed ID: 10667164
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration.
Hwang WL; Pleskow HM; Miyamoto DT
Adv Drug Deliv Rev; 2018 Feb; 125():122-131. PubMed ID: 29326053
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients.
Tomasetti M; Staffolani S; Nocchi L; Neuzil J; Strafella E; Manzella N; Mariotti L; Bracci M; Valentino M; Amati M; Santarelli L
Clin Biochem; 2012 May; 45(7-8):575-81. PubMed ID: 22374169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
